$1.77
8.76% day before yesterday
Nasdaq, Jan 02, 10:00 pm CET
ISIN
IL0011429839
Symbol
ENTX

Entera Bio Ltd. Stock price

$1.77
-0.45 20.27% 1M
-0.14 7.33% 6M
-0.17 8.76% YTD
-0.48 21.33% 1Y
+1.04 142.47% 3Y
+0.53 42.74% 5Y
-4.51 71.82% 10Y
-4.51 71.82% 20Y
Nasdaq, Closing price Fri, Jan 02 2026
-0.17 8.76%
ISIN
IL0011429839
Symbol
ENTX
Industry

Key metrics

Basic
Market capitalization
$81.2m
Enterprise Value
$72.6m
Net debt
positive
Cash
$8.6m
Shares outstanding
45.7m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
676.4 | 1,894.7
EV/Sales
605.0 | 1,694.7
EV/FCF
negative
P/B
5.3
Financial Health
Equity Ratio
86.1%
Return on Equity
-118.1%
ROCE
-68.3%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$120.0k | $42.8k
EBITDA
$-10.8m | -
EBIT
$-10.8m | $-13.0m
Net Income
$-10.8m | $-14.9m
Free Cash Flow
$-7.1m
Growth (TTM | estimate)
Revenue
20.0% | -76.2%
EBITDA
-52.0% | -
EBIT
-51.4% | -36.0%
Net Income
-50.6% | -56.2%
Free Cash Flow
11.2%
Margin (TTM | estimate)
Gross
0.0%
EBITDA
-8,701.6% | -
EBIT
-8,729.0%
Net
-8,694.4% | -34,788.6%
Free Cash Flow
-5,715.3%
More
EPS
$-0.2
FCF per Share
$-0.2
Short interest
0.3%
Employees
19
Rev per Employee
$10.0k
Show more

Is Entera Bio Ltd. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,082 stocks worldwide.

Entera Bio Ltd. Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Entera Bio Ltd. forecast:

6x Buy
86%
1x Hold
14%

Analyst Opinions

7 Analysts have issued a Entera Bio Ltd. forecast:

Buy
86%
Hold
14%

Financial data from Entera Bio Ltd.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
0.12 0.12
20% 20%
100%
- Direct Costs 0.12 0.12
33% 33%
100%
- -
-
-
- Selling and Administrative Expenses 5.34 5.34
48% 48%
4,450%
- Research and Development Expense 5.49 5.49
54% 54%
4,575%
-11 -11
52% 52%
-8,992%
- Depreciation and Amortization 0.03 0.03
40% 40%
25%
EBIT (Operating Income) EBIT -11 -11
51% 51%
-9,020%
Net Profit -11 -11
51% 51%
-8,983%

In millions USD.

Don't miss a Thing! We will send you all news about Entera Bio Ltd. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Entera Bio Ltd. Stock News

Neutral
GlobeNewsWire
11 days ago
FDA qualification of Total Hip BMD as a validated surrogate endpoint for novel osteoporosis drug development further bolsters Entera's July 2025 FDA alignment and regulatory strategy for EB613
Neutral
GlobeNewsWire
12 days ago
Novel PTH analog achieves sustained calcium elevation for >3 days from single oral tablet, supporting development path toward once-daily alternative to daily injections Novel PTH analog achieves sustained calcium elevation for >3 days from single oral tablet, supporting development path toward once-daily alternative to daily injections
Neutral
GlobeNewsWire
about 2 months ago
JERUSALEM, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (Nasdaq: ENTX), (“Entera” or the “Company”) a leader in the development of oral peptide and protein replacement therapies, today announced that the Company's Chief Executive Officer, Miranda Toledano, will be participating in a fireside chat at the 8th Annual Evercore ISI Healthcare Conference, details as below.
More Entera Bio Ltd. News

Company Profile

Entera Bio Ltd. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of orally delivered large molecule therapeutics. It develops an oral formulation of parathyroid hormone. The company was founded on June 1, 2010 and is headquartered in Jerusalem, Israel.

Head office Israel
CEO Miranda Toledano
Employees 19
Founded 2009
Website enterabio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today